Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

422
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
422
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.1K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.1K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

234
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
234
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

778
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
778
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.0K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Applied Astrobiology: An Integrated Approach to the Future of Life in Space.

Astrobiology·2025
Same author

Draining the brain: Gene therapy reverses brain edema in mice with the leukodystrophy MLC.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Gene Therapy for Inherited Liver Disease: To Add or to Edit.

International journal of molecular sciences·2024
Same author

Correction of Griscelli Syndrome Type 2 causing mutations in the <i>RAB27A</i> gene with CRISPR/Cas9.

Turkish journal of biology = Turk biyoloji dergisi·2024
Same author

Assessment of non-myelotoxic agents as a preparatory regimen for hematopoietic stem cell gene therapy.

Human cell·2024
Same author

Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations.

Molecular therapy : the journal of the American Society of Gene Therapy·2024

Related Experiment Video

Updated: Oct 2, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.2K

Gene Therapy Developments for Pompe Disease.

Zeenath Unnisa1, John K Yoon1, Jeffrey W Schindler1

  • 1AVROBIO, Inc., Cambridge, MA 02139, USA.

Biomedicines
|February 25, 2022
PubMed
Summary
This summary is machine-generated.

Gene therapy offers a promising new approach for Pompe disease, an inherited neuromuscular disorder. Adeno-associated virus (AAV) and lentiviral vector (LV) gene therapies show potential to overcome limitations of current treatments.

Keywords:
Pompe diseaseadeno-associated viral vectorenzyme replacement therapyhematopoietic stem celllentiviral vectors

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K

Related Experiment Videos

Last Updated: Oct 2, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.2K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K

Area of Science:

  • Neuromuscular disorders
  • Lysosomal storage diseases
  • Gene therapy

Background:

  • Pompe disease is an inherited neuromuscular disorder caused by acid alpha-glucosidase (GAA) deficiency.
  • Infantile-onset Pompe disease presents with severe cardiomyopathy and muscle weakness, while late-onset affects skeletal muscles.
  • Current enzyme replacement therapy has limitations including immunogenicity and inability to reach the central nervous system.

Purpose of the Study:

  • To review advancements in gene therapy for Pompe disease.
  • To highlight adeno-associated virus (AAV) and lentiviral vector (LV)-mediated hematopoietic stem and progenitor cell (HSPC) gene therapy approaches.
  • To discuss the potential of these gene therapies to address Pompe disease pathology.

Main Methods:

  • Review of current literature on gene therapy for Pompe disease.
  • Focus on AAV and LV HSPC-mediated gene therapy strategies.
  • Analysis of optimized viral vector designs and GAA protein modifications.

Main Results:

  • Optimized viral vectors and modified GAA proteins show improved preclinical efficacy and safety.
  • AAV and LV HSPC gene therapies demonstrate potential for multisystemic Pompe disease treatment.
  • These approaches aim to enhance GAA secretion and tissue uptake.

Conclusions:

  • Gene therapy, particularly AAV and LV HSPC-mediated approaches, represents a promising next-generation treatment for Pompe disease.
  • These therapies have the potential to overcome limitations of current enzyme replacement therapies.
  • Further development could provide a comprehensive solution for the neuromuscular aspects of Pompe disease.